ABOUT EVENT
2nd Obesity & Weight Loss Drug Development Summit – What’s Was It About?
United R&D Experts in Obesity & Weight Loss to revolutionize GLP-1 Combinations, Minimize Side Effects, Preserve Muscle Mass, Identify Novel Targets & More
GLP1R agonists from Novo Nordisk and Eli Lilly are booming, creating unprecedented benchmarks and demand for obesity therapeutics. But despite their blockbuster status, there is still room for competition in the obesity market as industry strives to meet unanswered questions with the next class of in-pipeline drugs.
How can tolerability and compliance be improved? Muscle mass and weight maintenance boosted? And how can the heterogeneity of obesity be addressed?
This summit unlocked industry decisions and insights into the promising next class of obesity therapeutics. Delving into Eli Lilly’s Orgorglipron and more, to explore the future of more tolerable second and third generations of GLP combinations. And beyond incretin-based approaches, examining novel advancements from Regeneron’s GPR75 modulator, Glaceum’s mitochondrial drug, Aardvark’s ARD-101, and Ercal’s ERA-379 to assess how the obesity and weight loss drug market is evolving.
Capturing biopharma’s latest research from target validation to translational drug development and clinical outcomes that meet the market opportunity, the 2nd Obesity & Weight Loss Drug Development Summit was the comprehensive forum dedicated to the evolving polypharmacy in the incretin obesity space.
Top 5 Unmissable Program Insights in 2024
Optimize study outcomes by building on real-world evidence and leveraging lessons learned from phase 3 Tirzepatide, Retatrutide and Orforglipron trials with Wave Life Sciences and Eli Lilly
Advance your knowledge on combatting human muscle mass loss through manipulation of skeletal muscle and exploitation of the TGF-b superfamily pathway with Six Peaks Bio
Discover the next generation of combination approaches using GIP, glucagon, amylin, FGF21 and evaluate the clinical potential of these candidates with Eli Lilly
Grasp unique viewpoints on assessing how genetic variants impact the MoA of obesity with Regeneron
Uncover novel approaches non-appetite suppression approaches from mitochondrial uncouplers, CCK mediated gut-brain signalling and GI tract targeting with Ercal, OrsoBio, Aardvark and Glyscend
DOWNLOAD THE 2024 EVENT GUIDE
Join our 18 expert speakers for 3 dynamic days of exploring the latest developments and cutting-edge innovations in the obesity and weight loss space.
Who Was in Attendance in 2024?
This summit stands as the hub of knowledge, showcasing the latest in developments in the incretin and non-incretin fields. 80+ experts immersed themselves in cutting edge obesity and weight loss drug development from target validation to clinical outcomes.
What Your Peers Have to Say
“It’s an exciting time to be developing new therapies for metabolic health. I look forward to learning more about how we can bend the curve of life by reducing and eliminating metabolic disease and its deadly complications.”
CEO, Myracle Therapeutics
‘’GLP-1 mimetics and their combinations have opened a new frontier in effective weight management. The real-world evidence on the efficacy and adherence for those drugs offer us new perspectives on the expectations for the next generation of anti-obesity treatments. I look forward to sharing these new developments at this exciting conference.’’
SVP, Wave Life Sciences
“It was a small-scale meeting where personal connections could be made, ample opportunity to do so, to discuss findings and perspectives in person.’’
Chair of Global Development, Regeneron
‘“The attendees, the quality of the speakers and the interaction and discussion we had led to a fantastic Summit.”
Director, Physiogenex